AbstractThe review summarizes literature data around the development of drugs based on natural and synthetic high-polymeric double-stranded RNA (dsRNA), their antiviral, immunoadjuvant, and antitumor properties. Larifan (produced by Larifan Ltd., Velneperit Latvia) is usually a drug made up of the replicative form of bacteriophage f2 dsRNA, obtained from cells infected with the phage. Based on phage dsRNA, several dosage forms have been developed: the injection form of Larifan, an antiviral and immunostimulatory drug with antitumor activity; Larifan ointment and suppositories [54]. Limited information exists around the development Velneperit of drugs based on other natural dsRNAs. One such example is usually dsRNA of bacteriophage 6 isolated from infected cells and representing a mixture of dsRNA of different lengths: 6.3 kb; 4.0?kb and 2.9 kb (L-, M- and S-forms, respectively). In a series of experimental studies, it has been shown that phage dsRNA exhibits high IFN-inducing and antiviral activity against viruses causing Omsk hemorrhagic fever and influenza computer virus A/Chicken/Kurgan/05/2005 (H5N1) [55C57]. Synthetic dsRNA is usually another type of high polymeric dsRNA widely used in pharmaceutical development. The history of synthetic double-stranded polyribonucleotide complexes began in 1955, when Grunberg-Manago and Ochoa showed that this enzyme polynucleotide phosphorylase (PNPase; EC 2.7.7.8) from in the presence of Mg2+ could catalyze the reaction of polynucleotide synthesis of a Velneperit certain structure up to 2C2.7 kb from ribonucleoside diphosphates with the release of stoichiometric amounts of orthophosphate [58]. Subsequently, double-stranded complexes were obtained from complementary polyribonucleotides by annealing. The development of simple methods for synthesis of high-polymer dsRNA has opened the chance of making them in enough quantities to review and create medications on the basis. In some tests by Vilner et al. [59, 60] it had been proven the fact that antiviral activity of artificial polyribonucleotides considerably depended in the polymer duration (now it really is clear, that it’s dependant on the specificity of receptor binding). Predicated on the full total outcomes of natural research, PolyA:PolyU, PolyG:PolyC, and PolyI:PolyC exhibiting one of the most pronounced IFN-inducing and antiviral activity had been chosen for even more research. As was proven in in vitro and in vivo tests, PolyA:PolyU suppresses duplication of herpes infections, infections of reproductive respiratory syndrome , transmissible gastroenteritis, and African swine fever [61, 62]. It is an active IFN inducer, although its ability to enhance interferon synthesis and to increase the survival of mice in experimental viral infections, was a bit lower than of PolyG:PolyC and PolyI:PolyC [61]. Currently, on the basis of PolyA:PolyU, the drug Poludan (manufactured by Lance-Farm LLC, Russia) has been developed and registered. It is usually used in the form of vision and nasal drops in viral vision diseases (adenoviral and herpetic keratoconjunctivitis, keratitis, keratoiridocyclitis, etc.), in complex therapy of influenza and other acute respiratory infections. You will find data around the clinical trials of the foreign drug analogue Polyadenur (PolyA:PolyU with a molecular mass ranged from 250 kDa to 1500 kDa). It has been developed by Beaufour Ipsen (France) together with Hemispherx Biopharma (USA), for using as a component of complex therapy (in combination with IFN-) of hepatitis B and C, and also for treatment of breast malignancy [63C65]. According to the classification proposed by Yershov et al., the Rabbit Polyclonal to BID (p15, Cleaved-Asn62) PolyG:PolyC and PolyI:PolyC based drugs are referred to the group of highly active IFN inducers (IFN titers at the peak of the response of more than 1000 models/mL) with pronounced antiviral activity [61]. Studies of the complex of double-stranded polyriboguanylic and polyribocytidylic acids (PolyG:PolyC, Polyguacyl) performed in the 1970sC1980s, showed that the drug had a Velneperit broad spectrum of antiviral activity and could be effective in the acute phase of viral hepatitis and encephalitis, for the treatment of influenza and rabies [61, 66]. However, a number of significant drawbacks, such as the uncertainty of the chemical structure, the lack of homogeneity and, as a result, the unpredictable pharmacokinetics and toxicity of Polyguacyl became a serious obstacle to its clinical use [46, 67]. In 2013, experts from Riboxx GmbH (Germany) developed a modified method for generating PolyG:PolyC to overcome these drawbacks. The new?drug RGC100 was characterized.